Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses by Boesch, Austin W et al.
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
12-13-2016
Biophysical and Functional Characterization of











See next page for additional authors
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Animal Sciences Commons, Cell Biology Commons, and the Genetics and Genomics
Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Boesch, Austin W.; Osei-Owusu, Nana Yaw; Crowley, Andrew R.; Chu, Thach H.; Chan, Ying; Weiner, Joshua; Bharadwaj, Pranay;
Hards, Rufus; Adamo, Mark; Gerber, Scott; Cocklin, Sarah; Schmitz, Joern; Miles, Adam; Eckman, Joshua; Belli, Aaron J.; Reimann,
Keith; and Ackerman, Margaret E., "Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses" (2016). Open
Dartmouth: Faculty Open Access Articles. 2562.
https://digitalcommons.dartmouth.edu/facoa/2562
Authors
Austin W. Boesch, Nana Yaw Osei-Owusu, Andrew R. Crowley, Thach H. Chu, Ying Chan, Joshua Weiner,
Pranay Bharadwaj, Rufus Hards, Mark Adamo, Scott Gerber, Sarah Cocklin, Joern Schmitz, Adam Miles,
Joshua Eckman, Aaron J. Belli, Keith Reimann, and Margaret E. Ackerman
This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/2562
December 2016 | Volume 7 | Article 5891
Original research
published: 13 December 2016
doi: 10.3389/fimmu.2016.00589
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Harry W. Schroeder, 




National Cancer Institute, USA 
Neil S. Greenspan, 
Case Western Reserve University, 
USA
*Correspondence:




This article was submitted to 
B Cell Biology, 







Crowley AR, Chu TH, Chan YN, 
Weiner JA, Bharadwaj P, Hards R, 
Adamo ME, Gerber SA, Cocklin SL, 
Schmitz JE, Miles AR, Eckman JW, 
Belli AJ, Reimann KA and 
Ackerman ME (2016) Biophysical and 
Functional Characterization of Rhesus 
Macaque IgG Subclasses. 
Front. Immunol. 7:589. 
doi: 10.3389/fimmu.2016.00589
Biophysical and Functional 
characterization of rhesus 
Macaque igg subclasses
 
Austin W. Boesch1, Nana Yaw Osei-Owusu2, Andrew R. Crowley2, Thach H. Chu1,  
Ying N. Chan1, Joshua A. Weiner1, Pranay Bharadwaj2, Rufus Hards2,3, Mark E. Adamo4, 
Scott A. Gerber2,3,4, Sarah L. Cocklin5, Joern E. Schmitz5, Adam R. Miles6,  
Joshua W. Eckman6, Aaron J. Belli7, Keith A. Reimann7 and Margaret E. Ackerman1,2*
1 Thayer School of Engineering, Dartmouth College, Hanover, NH, USA, 2 Molecular and Cellular Biology Program, Dartmouth 
College, Hanover, NH, USA, 3 Department of Genetics and Biochemistry, Geisel School of Medicine, Hanover, NH, USA, 
4 Norris Cotton Cancer Center, Geisel School of Medicine, Lebanon, NH, USA, 5 Center for Virology and Vaccine Research, 
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA, 6 Wasatch Microfluidics, Salt Lake City, 
UT, USA, 7 Non-Human Primate Reagent Resource, MassBiologics of the University of Massachusetts Medical School, 
Boston, MA, USA
Antibodies raised in Indian rhesus macaques [Macaca mulatta (MM)] in many preclinical 
vaccine studies are often evaluated in vitro for titer, antigen-recognition breadth, neu-
tralization potency, and/or effector function, and in vivo for potential associations with 
protection. However, despite reliance on this key animal model in translation of promising 
candidate vaccines for evaluation in first in man studies, little is known about the proper-
ties of MM immunoglobulin G (IgG) subclasses and how they may compare to human IgG 
subclasses. Here, we evaluate the binding of MM IgG1, IgG2, IgG3, and IgG4 to human 
Fc gamma receptors (FcγR) and their ability to elicit the effector functions of human 
FcγR-bearing cells, and unlike in humans, find a notable absence of subclasses with 
dramatically silent Fc regions. Biophysical, in vitro, and in vivo characterization revealed 
MM IgG1 exhibited the greatest effector function activity followed by IgG2 and then 
IgG3/4. These findings in rhesus are in contrast with the canonical understanding that 
IgG1 and IgG3 dominate effector function in humans, indicating that subclass-switching 
profiles observed in rhesus studies may not strictly recapitulate those observed in human 
vaccine studies.
Keywords: igg, rhesus, effector function, non-human primate, Fc receptor
inTrODUcTiOn
Studies in non-human primates (NHP) are often a key aspect of preclinical vaccine development. 
Antibodies raised in NHP in such studies are often evaluated in vitro for titer, antigen-recognition 
breadth, and neutralization potency or effector function, as well as in vivo for potential associations 
with protection. These studies are conducted in settings ranging from simian immunodeficiency 
virus (SIV) or simian/human immunodeficiency virus, to TB, yellow fever, dengue, and malaria, 
among many others, with a goal of evaluating and understanding vaccine-mediated protection (1). 
However, despite reliance on NHP in translation of promising candidate vaccines and the estab-
lished significance of antibody interactions with Fc gamma receptors (FcγR) as key contributions to 
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antibody activity in vivo, little is known about the properties of 
NHP immunoglobulin G (IgG) subclasses. The widespread use 
of NHP in preclinical studies aimed at evaluating the possible 
efficacy of candidate vaccines, and the accumulating evidence 
that Fc-dependent activities strongly contribute to antibody-
mediated protection, encourages functional characterization of 
IgG subclasses in these crucial model organisms.
For example, Indian rhesus macaques [Macaca mulatta 
(MM)] have been used extensively for evaluating antibody-based 
correlates of vaccine-mediated protection, and in several stud-
ies, antibody effector functions have been implicated as critical 
components of protection against SIV infection (2–5). However, 
despite these associations with protective efficacy, little is known 
about the functional characteristics of MM IgG subclasses. 
Reliance on these animal models in evaluation of candidate 
vaccines dictates closer evaluation of NHP IgG immunobiol-
ogy, as despite evolutionary proximity, there may be important 
immunological differences between species.
In humans, antibody responses associated with differential 
IgG subclass compositions across different pathogen or antigen 
types are well known, and in some cases protection or pathology 
has been found to associate with variation in subclass selection. 
While a number of studies have investigated IgG subclasses 
in NHP (6, 7), the majority of this effort has been directed at 
defining subclass sequences; despite small study cohort sizes, 
this work has suggested significant allotypic diversity in IgA 
(8, 9). Previous experimental work has begun to elucidate the 
landscape of antibody properties in NHP but has not converged 
to yield a consensus understanding of the functions of primate 
IgG subclasses. Perplexingly, in an early experimental study 
aimed at functional characterization of cynomolgus macaque 
IgG subclasses, investigators observed similar subclass activi-
ties as in human (10), while a more recent investigation found 
divergent activity profiles between human and macaque IgG 
subclasses (11).
Here, we seek to evaluate the functional activity of MM IgG 
subclasses with the aim of enabling comparison of immunoglob-
ulin biology between species. Evaluating species-mismatched 
antibodies and receptors is also relevant to the widespread use 
of human effector cells to evaluate the potency of rhesus serum 
IgGs elicited in vaccine studies, in which effector functions 
such as antibody-dependent cellular cytotoxicity (ADCC) (2, 5, 
12–15), virus inhibition (ADCVI) (12, 16, 17), or phagocytosis 
(ADCP) (5, 15, 18) activities are often determined. These in vitro 
data help inform the potential mechanistic contributions of 
effector function to in vivo observations of protection or viremic 
control during vaccination or passive transfer studies in the NHP 
model and enable insight into vaccine and therapeutic design for 
humans. As a practical matter, the use of rhesus peripheral blood 
mononuclear cells (PBMCs) in effector assays is avoided due to 
their high inherent natural killer (NK) lytic activity and capacity 
to kill SIV-infected target cells. As a result, despite the species 
mismatch, the use of human target cells and human PBMCs in 
assessing the functional quality of rhesus antibody responses is 
specifically advised (2, 12, 19).
The use of human cell lines or PBMCs has enabled simple, 
reliable, and highly sensitive assays to assess rhesus macaque IgG 
effector functions and has eased comparison to in vivo results or 
to the in vitro functional activity of human IgGs. For example, 
the human PBMC ADCC activity of vaccine-elicited, serum-
derived rhesus IgG has correlated to reduced acute viremia after 
intravaginal (2) and intrarectal (13) challenge with pathogenic 
SIV in vivo. Both ADCC and ADCVI assays using human PBMCs 
with rhesus anti-SIV IgG have been used to assess Ab potency in 
passive transfer studies (12). Additionally, the use of the human 
monocytic THP-1 cell line has been used to differentiate the 
phagocytic potential of vaccine-elicited rhesus serum IgG (18). 
Most importantly, such species-mismatched functional evalua-
tions of antibody activity have correlated with protection from 
viral infection in recent challenge studies (5, 15).
Despite the prevalence of leveraging human effector cells to 
analyze the functionality of rhesus IgGs in vaccine and passive 
transfer studies, there is little known about the biophysical 
characteristics of rhesus IgG interacting with human FcγR. Here, 
we characterize the ability of recombinant rhesus IgG1, IgG2, 
IgG3, and IgG4 to interact with human FcγR and to induce the 
effector functions of human FcγR-bearing innate immune cells in 
order to investigate differences and similarities between species 
in terms of IgG subclass biology. As interspecies and intraspecies 
differences in IgG sequence and function pose potential caveats 
to the translation of findings in these key animal models, better 
understanding of antibody immunobiology in primates may 
prove key to enhancing the design and evaluation of future vac-
cine candidates.
MaTerials anD MeThODs
construction, expression, and  
Purification of igg and Fcγr
To construct reference MM IgG of different subclasses, total RNA 
was isolated from 106 mouse hybridoma cells expressing anti-
CD8α monoclonal antibody, M-T807 (20) using RNAqueous-
4PCR kit (Ambion Inc., Austin, TX, USA). A cDNA library 
was produced using SMARTer™ RACE cDNA Amplification 
Kit (Clontech, Mountain View, CA, USA). DNA encoding the 
variable domains of the heavy (VH) and the light chain (VL) 
were amplified using Advantage 2 PCR Kits (Clontech) with 
IgG1H (5′-ACCAAC GCTGCAGGTGACGGTCTGAC-3′) and 
IgG1k (5′-CTAACACTCATTCCTGTTGAAGCTCTTGAC-3′), 
cloned into the pCR 2.1-TOPO vector, used to transform One 
Shot TOP10 Chemically Competent E. coli (Invitrogen), and 
sequences confirmed. Three different rhesus recombinant 
versions of M-T807 were developed by grafting the CDRs, as 
defined by Kabat et  al. (21), using rhesus Ig germline variable 
region sequences (NCBI accession numbers XP_0010960271 and 
XP_0011060902) as templates. Key positions potentially contrib-
uting to antigen binding, CDR conformation, and heavy–light 
chain interactions were back-mutated to the mouse residues. 
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expression vectors containing rhesus IgG1 heavy chain (CH) and 
rhesus kappa light chain (CL) constant regions cloned from a 
rhesus B-lymphoblastoid cell line by PCR amplification. Rhesus 
recombinant antibodies representing each H + L chain combina-
tion were transiently expressed at small scale in HEK293 cells by 
co-transfection of recombinant light and heavy chain expression 
vectors using Lipofectamine (Invitrogen) and purified by Protein 
A affinity chromatography (GE Health Care). The CDR-grafted 
H + L chain pair that yielded the highest relative affinity antibody 
measured using a CD8α-expressing cell-based ELISA assay was 
used for all further experiments. The CDR-grafted VH segments 
were also subcloned into rhesus IgG2, IgG3, or IgG4 CH expres-
sion vectors, using rhesus gamma chain sequences previously 
reported (9), to permit expression of rhesus recombinant antibody 
of different IgG subclasses but sharing identical variable regions.
For large-scale production of rhesus antibodies, recombinant 
heavy and light chain vectors were packaged in retroviral vectors 
and used to infect CHO cells using the GPEx™ expression plat-
form (Catalent Pharma Solutions, Madison, WI, USA). A pool of 
transduced cells was grown in serum-free medium from which 
recombinant antibodies were purified by protein A affinity chro-
matography and formulated in phosphate buffer at pH 6.5–8.0, 
based on each antibody’s isoelectric point. Endotoxin levels were 
<1  EU/mg of antibody. Recombinant rhesus antibody samples 
used in binding assays were SEC purified until aggregated IgG 
was undetectable (i.e., less than one part per thousand), and the 
monomeric fraction was used for all studies with the exception of 
IgG samples used in deglycosylation experiments.
Pooled polyclonal rhesus IgG purified from serum was 
obtained from the NHP Reagent Resource, and IgG from rhesus 
serum from a set of 47 Indian-origin rhesus macaques was evalu-
ated either following dilution or after depletion of other com-
mon serum proteins using Melon gel (Thermo Pierce). Human 
IgG1, IgG2, and IgG4 myeloma proteins were obtained from 
Athens Research Corporation, while IgG3 myeloma protein was 
obtained from Sigma-Aldrich. The purity of these commercial 
preparations was described as >90%. The human VRC01 mAb 
was subclass-switched into IgG2, IgG3, and IgG4 forms as follows. 
Human IgG subclass backbone plasmids were obtained from 
Invivogen (pFUSEss-CHIg-hG2, pFUSEss-CHIg-hG3, pFUSEss-
CHIg-hG4). The entire VRC-01 variable region was cloned out of 
the parent pCMV VRC01 IgG1 HC plasmid (NIH AIDS Reagent 
Program) and inserted into each individual subclass backbone 
plasmid. Sequencing was performed to confirm variable region 
insertion. Subsequently, each VRC-01 subclass gene was cloned 
back into an empty pCMV plasmid to maximize dual expression 
of the heavy chain with the pCMV VRC01 IgG1 LC plasmid (NIH 
AIDS Reagent Program).
The glycosylation profile of recombinant MM IgG subclasses 
and of polyclonal, serum-derived MM IgG was determined by 
HPLC as previously described (22). Human FcγRs were expressed 
and purified as previously described (23).
MM anti-subclass Detection reagents
A set of anti-MM IgG subclass detection monoclonal antibod-
ies was developed as follows. Mice were immunized with 
baboon (P. anubis) serum IgG, and resulting hybridomas were 
screened for species and subclass specificity, resulting in isola-
tion of a clone (7H11) with good specificity for MM IgG1, and 
minor recognition of MM IgG3. In order to generate mono-
clonal antibodies specific for MM IgG2 and IgG3, mice were 
immunized with peptides derived from the IgG hinge region, 
where MM subclasses demonstrate significant differences. The 
overlapping peptides VVHEPSNTKVDKTVGLPCRSTCPPCP 
and DKTVGLPCRSTCPPCPAELLGCPSVF were used 
to generate anti-IgG2 responses, whereas the peptide 
DKRVEFTPPCGDTTPPCPPPCPP was used to generate anti-
IgG3 responses. Resulting antibodies were extensively screened 
for specificity and sensitivity, and clones 3C10 (anti-MM IgG2) 
and 2G11 (anti-MM IgG3) were identified. Similar approaches 
to immunize mice with IgG4 hinge peptides failed to generate 
monoclonal antibodies that bound specifically to MM IgG4. All 
reference IgGs and anti-subclass detecting antibodies are avail-
able through the NHP Reagent Resource.
structure Visualization and Manipulation
Immunoglobulin G alignments were generated using Geneious 
and ClustalW2. Sequences and coordinates for human IgG1 in 
complex with FcγRIIIb were retrieved from the Protein Data 
Bank (PDB) entry 1T89. FcγRI (PDB 4W4O) was aligned to 
FcγRIIIb (PDB 1T89), and contact residues were determined 
from the combined model using a cutoff distance of 5  Å. All 
structure manipulations and visualizations were performed in 
Chimera version 1.10.1 (24). Macaque sequences were retrieved 
from Scinicariello et  al. (9), and human IgG sequences were 
from Uniprot P01857, P01859, P01860, and P01861. ClustalW2 
alignments were used in Chimera to render by conservation. All 
protein structures shown are from 1T89 only.
endos and Pngase F Treatment of igg
For EndoS treatment of IgGs, 100 µg of MM monoclonal IgGs 
(NHP Reagent Resource) were treated with 2  µg of 1  mg/mL 
EndoS (gift from Dr. Kavitha Baruah from Oxford University) 
overnight at 37°C. EndoS is an enzyme from S. pyogenes that is 
highly specific for cleaving the IgG Fc glycan following the initial 
variably fucosylated N-acetylglucosamine (25). EndoS in the 
samples were inactivated by incubation at 55°C for 10 min. For 
PNGase F treatment of IgGs (to remove the entire Fc glycan), 
0.5 µL of Remove-iT PNGase F (NEB) was added to each 100 µg 
sample of IgG and incubated for 24  h at 37°C. The PNGase F 
was then removed using chitin magnetic beads according to the 
protocol provided by New England Biolabs. Glycan removal was 
confirmed by running 2  µg of each DTT reduced IgG sample 
on a 4–12% bis-tris gel and observing a 3-kDa decrease in the 
molecular weight for the IgG heavy chain. Further confirmation 
was provided by lectin western blot (data not shown).
Multiplex igg subclassing and human 
Fcγr Binding assay
Purified, monomeric Hu FcγR or subclass-specific MM IgG detec-
tion reagents (7H11, 3C10, 2G11 clones, NHP Reagent Resource) 
were coupled to carboxylated magnetic beads (Luminex Corp.) 
using amine reactive chemistry as described previously (26). In 
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an adaptation of a previously described protocol (23), antibody 
samples were serially diluted in 0.05% Tween-PBS in non-binding, 
clear-bottom black 384 well plates (Corning) in a total volume 
of 40 µL and for every dilution series, an additional well lacking 
test antibody was evaluated to determine background signal. A 
master bead mix containing all the receptor detection bead sets 
of interest was prepared in 0.05% Tween-PBS at a concentration 
of 50,000  beads/mL for each bead set. A 10-µL volume of this 
master bead mix was added to each well-containing antibody 
sample to reach a final volume of 50 µL. The plate was sonicated 
for 10–20 s to mix and then placed on an XYZ plate shaker (IKA) 
at 800 rpm for 2 h at room temperature. Unbound antibody was 
removed by washing the plate using an automatic plate washer 
(Biotek) fitted with a plate magnet and programed to conduct 
five washes with 60  µL of 0.05% Tween-PBS. Next, 40  µL of a 
0.65 µg/mL goat anti-rhesus heavy and light chain-PE (Southern 
Biotech) in 0.05% Tween-PBS solution was added to each well, 
and the plate was sonicated and shaken at 800  rpm at room 
temperature for 1 h. The plate was washed again, and 35 µL of 
sheath fluid was used to resuspend beads in each well for analysis 
on a FlexMap 3D (Luminex Corp.). At least 35 beads for each 
bead set were analyzed. The average background MFI signal from 
wells that lacked antibody was subtracted from the signal from 
antibody-containing wells to account for any non-specific bind-
ing of detection reagent to beads. For all detection reagents, the 
magnitude of fluorescence observed from non-specific binding of 
detection reagent to the beads was comparable to that when beads 
are run in the absence of detection reagent (data not shown). 
Background-subtracted data were analyzed in GraphPad Prism, 
and non-linear regression trend lines were fit using the one site, 
specific binding model.
elisa subclassing assays
Specificity of MM anti-subclass detection antibodies was 
evaluated by ELISA, in which plates were functionalized with the 
extracellular domain of rhesus macaque CD8α protein, incubated 
with the recombinant anti-CD8α MM IgGs, and detected by 
the anti-subclass detection reagents. ELISA plates were coated 
overnight at 4°C with 0.5 µg/mL goat anti-HIS tag monoclonal 
antibody diluted in carbonate–bicarbonate buffer, pH 9.0, then 
blocked with Superblock at room temperature for 45  min. 
Recombinantly expressed and purified rhesus CD8α-HIS (NHP 
Reagent Resource) was applied at 5 µg/mL in 2% BSA for 1 h. 
Monoclonal anti-rhesus CD8α antibodies (IgG1–4) were applied 
for 1 h at 10 µg/mL in 2% BSA. Bound MM IgG was detected 
using the anti-rhesus IgG subclassing reagents described above 
diluted to 20  µg/mL in 2% BSA over a fourfold serial dilution 
range. After incubation for 1 h, bound subclass detection reagents 
were detected using a 1:1,000 dilution of a goat anti-mouse IgG 
(H + L) HRP in 2% BSA for 1 h, which was visualized with peroxi-
dase substrate after a 4-min incubation at room temperature prior 
to stopping and reading out the product formation at OD 450 nm.
The presence of each IgG subclass in a single, pooled MM 
serum sample was evaluated similarly, with the exception that 
each recombinant MM IgG subclass and a MM serum sample 
were adhered directly to ELISA plates, followed by incubation 
with anti-subclass detection reagents over a dilution curve prior 
to development and absorbance measurements, essentially as 
described. Data were analyzed in GraphPad Prism, and non-
linear regression trend lines were fit using the one site, specific 
binding model.
lc–Ms/Ms analysis of igg subclasses
Macaca mulatta serum from Indian-origin rhesus macaques and 
individual and defined mixtures of recombinant IgG subclass 
standards were reduced and separated by SDS-PAGE. Briefly, 
10 µL of reduced and alkylated sample, at an estimated (serum) 
or exact (recombinant) IgG concentration of 0.167 mg/mL, was 
loaded into individual wells of a 15-well NuPAGE 4–12% bis-
tris gel (ThermoFisher) and run at 200 V for 45 min, followed by 
visualization with Coomassie blue stain, band excision of the IgG 
HC, and in-gel digestion per standard procedures with sequenc-
ing grade trypsin (Promega). Peptide digests were analyzed by 
online microcapillary LC–MS/MS using an EasyLC-1000 UPLC 
and Q Exactive Plus mass spectrometer platform. Peptides 
were resuspended in 5% methanol/1% formic acid and loaded 
on to a trap column [1  cm length, 100  µm inner diameter, 
ReproSil, C18 AQ 5 µm 120 Å pore (Dr. Maisch, Ammerbuch, 
Germany)], vented to waste via a micro-tee, and eluted across 
a fritless analytical resolving column (35  cm length, 100  µm 
inner diameter, ReproSil, C18 AQ 3  µm 120  Å pore) pulled 
in-house (Sutter P-2000, Sutter Instruments, San Francisco, 
CA, USA) with a 60-min gradient of 5–30% LC-MS buffer B 
(LC-MS buffer A: 0.0625% formic acid, 3% ACN; LC-MS buffer 
B: 0.0625% formic acid, 95% ACN). The Q Exactive Plus was set 
to perform an Orbitrap MS1 scan (R = 70 K; AGC target = 3e6) 
from 350 to 1,500 Th, followed by HCD MS2 spectra on the 10 
most abundant precursor ions detected by Orbitrap scanning 
(R = 17.5 K; AGC target = 1e5; max ion time = 75 ms) before 
repeating the cycle. Precursor ions were isolated for HCD by 
quadrupole isolation at width = 0.8 Th and HCD fragmentation 
at 26 normalized collision energy. Charge state 2, 3, and 4 ions 
were selected for MS2. Precursor ions were added to a dynamic 
exclusion list ± 20 ppm for 20 s. Raw data were searched using 
COMET (release version 2014.01) in high resolution mode (27) 
against a FASTA database containing all four IgG subclasses 
with a precursor mass tolerance of ±1 Da and a fragment ion 
mass tolerance of 0.02 Da, and requiring fully tryptic peptides 
(K, R; not preceding P) with up to three miscleavages. Static 
modifications included carbamidomethylcysteine, and oxidized 
methionine was the variable modification. Searches were fil-
tered using orthogonal measures including mass measurement 
accuracy (±3 ppm), Xcorr for charges from +2 through +4, and 
dCn targeting a <1% FDR at the peptide level. Quantification 
of LC–MS/MS spectra was performed using MassChroQ (28). 
Annotated spectra and details of the peptides observed for 
each sample are provided in Files S1 and S2 in Supplementary 
Material, respectively.
surface Plasmon resonance  
(sPr) affinity Measurements
Surface plasmon resonance was used to measure equilibrium 
binding affinities. A Continuous Flow Microspotter (CFM) 
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(Wasatch Microfluidics) was used to print up to 96 indi-
vidual regions of interests (ROI) on a single gold prism surface 
coated with carboxymethyldextran substrate (200  M Xantec 
Bioanalytics). CFM fluid paths were primed with 25 mM sodium 
acetate pH 5.0 + 0.01% Tween 20 prior to activation. The substrate 
of each ROI was activated for 5–7 min with 100 µL of 1.2 mM 
N-hydroxysulfosuccinimide (sNHS) (Pierce) and 0.3  mM 
1-ethyl-3-[3 dimethlyaminopropyl]carbodiimide-HCl (EDC) 
(Pierce) in deionized water under flow at 45 µL/min. Antibodies 
prepared at 50, 25, 12.5, and 6.25 µg/mL in 25 mM sodium acetate 
pH 4.5–5.0 and printed on the activated ROI at the four resulting 
ligand (IgG) densities. A direct IgG coupling method was used 
since a suitable rhesus-specific capture reagent with a sufficiently 
slow off rate across all rhesus IgG subclass could not be identi-
fied. The image-based array reader (MX96, IBIS Technologies) 
was primed with 25 mM sodium acetate pH 5.0 + 0.01% Tween 
20 and the prism loaded and quenched with 120  µL of 0.5  M 
ethanolamine (Sigma-Aldrich) prior to priming, conditioning, 
and analyte injections. FcγRs were diluted in running buffer 
(PBS + 0.01% BSA + Tween 20) and injected over an eight part, 
threefold serial dilution series, generally starting between 18 and 
41 µM, and consisting of the following steps: 0.5-min baseline, 
5-min association, 5-min dissociation, and 0.5-min baseline. The 
prism was regenerated with 0.5 min 100 mM glycine pH 3.0 and 
0.5 min baseline between each analyte (FcγR) dilution tested. ROI 
signal was double referenced using signal from blank injections 
and signal from uncoupled interspots to account for non-specific 
binding. Data were processed in Scrubber 2 (Biologic Software 
Ltd.) by kinetic analysis applying global analysis to determine the 
equilibrium dissociation constant, KD. Steady-state analysis to 
calculate KD yielded similar values. Genetically and enzymatically 
deglycosylated human IgG1 and a panel of mAbs and Fc point 
mutants were used as controls and recapitulated the expected 
patterns of FcγR recognition preferences (data not shown). 
Experiments were repeated 2 to 12 times with different conjuga-
tion densities and print pH conditions. Data from two separate 
experiments using different preparations of FcγRs, each with 
multiple print spots for each IgG sample are presented.
In Vitro Functional assays
Natural Killer Cell Degranulation
The ADCC potential of MM IgG subclasses was assessed by an 
adaptation of previously described assays (29, 30) in which NK 
cell degranulation is measured based on CD107a surface expres-
sion, a marker correlated with human NK cell cytokine release, 
cytotoxic activity (29), and ADCC, in the presence of human 
IgGs (31, 32) as well as rhesus macaque serum samples (14). The 
NK-92 human NK cell line (NantKwest, formerly Conkwest) was 
cultured in tissue culture flasks at 37°C, 5% CO2, with passaging 
every 3–4 days from 50 to 600,000 cell/mL using RPMI 1640 sup-
plemented with l-glutamine, horse, and bovine sera, 100 U/mL 
IL-2 (AIDS Reagent Resource), and MEM non-essential amino 
acids. Sterile, 96-well polystyrene plates (Costar) were coated 
overnight at 4°C with a dilution series of each test IgG, diluted 
in PBS. Plates were washed and blocked using 1% BSA in PBS at 
room temperature. Each well received 2–10 × 103 and 0.2 test vol-
umes of anti-human CD107a detection reagent in a total volume 
of 200 µL. On each plate, two blocked wells received 2.5 μg/mL 
PMA and 0.5 µg/mL ionomycin as positive controls, while two 
blocked wells containing no antibody or cell stimulant served 
as negative controls. Following an 1-h incubation of the plates 
under 37°C, 5% CO2 conditions, Brefeldin A (final concentration 
of 10 µg/mL) and mononensin (GolgiStop, final concentration of 
6 µg/mL) were added to each well and the plates incubated for 
another 3–5 h. After incubation, cells were washed with cold PBS, 
pelleted at 400 × g in a chilled (4°C) centrifuge, and resuspended 
in fixative prepared in PBS. Fixation of cells occurred during a 
15-min, room temperature incubation that was shielded from 
light, and the reaction was subsequently quenched using PBS 
containing 5% serum protein. The quenching buffer was used for 
a final wash before resuspension in PBSF (PBS + 0.1% BSA). Data 
were acquired on a MACSQuant flow cytometer and analyzed 
using Flowjo V10 and GraphPad Prism. Non-linear regression 
trend lines were fit using the one site, specific binding model. 
ADCC assays were repeated five times, either in duplicate or 
triplicate.
Antibody-Dependent Cellular Phagocytosis
The phagocytic activity of human myeloma and MM IgG 
subclasses was assessed by adaptation of previously described 
phagocytosis assay (33). Briefly, 1  µm, yellow–green fluores-
cent FluoSpheres® Carboxylate-Modified Microspheres (Life 
Technologies) were conjugated with rhesus CD8α extracellular 
domain protein (NHP Reagent Resource, NIH, MM IgG subclass 
apparent affinity ranged 1.2- to 1.4-fold across subclasses) for 
evaluation of MM subclasses, or anti-human IgG Fab (Jackson 
Immunoresearch, human IgG subclass apparent affinity ranged 
1.2- to 2.5-fold across subclasses) for analysis of human myeloma-
derived subclasses, and diluted to 800,000 beads per 50  µL in 
RPMI 1640 with l-glutamine (Corning), 10% FBS (Biowest), 
and 1× Penicillin/Streptomycin/Amphotericin (Corning). The 
THP-1 human monocyte cell line (gift from Dr. Brent Berwin) 
was used as the effector cell population, and cells were diluted to 
20,000 cells per 150 µL RPMI. The assay was run in a 96-well tis-
sue culture plate by pipetting 50 μL of beads, then 150 µL of cells, 
and lastly 50 µL of RPMI alone or antibody diluted in RPMI at 5× 
the final target concentration. The cells were incubated at 37°C at 
5% CO2 for 4 h. After incubation, cells were fixed as described for 
the degranulation assay. Data were acquired on a MACSQuant 
flow cytometer and analyzed using Flowjo V10. A background-
subtracted phagocytosis score was calculated by multiplying 
the percentage of bead positive cells by their MFI, followed by 
subtraction of the phagocytosis score observed in the absence of 
antibody. Data were analyzed in GraphPad Prism, and non-linear 
regression trend lines were fit using the one site, specific binding 
model. ADCP assays were repeated five times, either in duplicate 
or triplicate. Equivalent opsonization of beads with each subclass 
was experimentally confirmed.
In Vivo Depletion activity
Antibody Administration to Animals
Indian rhesus monkeys (MM) were administered a single 
50 mg/kg dose of recombinant MM IgG anti-CD8α antibodies 
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comprising the four MM IgG subclasses by intravenous injec-
tion. Blood samples were periodically drawn to assess the effect 
of each subclass on depletion of CD8+ lymphocytes. For all 
injections and blood sampling, animals were anesthetized with 
ketamine HCl. All animals were maintained in accordance with 
the guidelines of the Committee on Animals for the Harvard 
Medical School and the Guide for the Care and Use of Laboratory 
Animals (34).
Lymphocyte Immunophenotyping
Lymphocytes in peripheral blood were immunophenotyped 
using EDTA-anticoagulated blood specimens in a whole blood 
lysis technique. Fluorochrome-conjugated antibodies were 
incubated with 100 µL of whole blood or lymph node cell sus-
pension for 20 min at room temperature. Antibodies used were 
anti-CD3 (SP34)-APC, anti-CD4-FITC (L200) (BD Bioscience), 
and anti-CD8-PE (DK25, Dako, Inc., Carpenteria, CA, USA). 
Erythrocytes were lysed using the Immunoprep Reagent System 
and a TQ-Prep Workstation (Beckman Coulter). To reduce 
the background level of staining, lysed samples were washed 
with 1.0 mL PBS, centrifuged for 3 min at 300 × g and fixed in 
PBS/1% formalin. Specimens were routinely analyzed for immu-
nofluorescence on a BD FACSCalibur (BD Bioscience) using a 
manually determined scattergate to gate lymphocytes. Absolute 
lymphocyte counts on blood specimens were obtained using an 
ADVIA 120 Hematology Analyzer (Siemens Medical Solutions 
USA, Malvern, PA, USA).
resUlTs
sequence and structural Differences 
among igg subclasses
The four IgG subclasses known to be present in MM were aligned 
with the CH2 domain of human IgG subclasses. Annotation 
of FcγR contact residues from co-crystal structures available 
for the high affinity FcγRI (35), low affinity FcγRIIa (36), and 
FcγRIIIa (37, 38) (Figure  1A) suggests that most MM IgG 
types are most similar to human IgG1 among predicted contact 
residues. As captured in a sequence identity matrix (Table 1), 
MM IgG were generally more similar to each other than to any 
human subclass. Thus, subclass numbering between species is 
not strictly consistent with overall sequence similarity between 
species across the entire Fc domain; further, rhesus subclasses 
tended to be more similar to human IgG1 than any other human 
subclass within the CH2 region responsible for recognition by 
FcγR. This sequence comparison suggests that MM IgG may 
function most similarly to human IgG1 and implies they may 
not exhibit the broad range of effector activities present among 
human IgG subclasses.
When sites of sequence variation between human and MM 
IgG1 are plotted on a rendering of the Fc–FcγR co-crystal 
structure, it is similarly apparent that most of the substitu-
tions between species are located distal to FcγR contact residues 
(Figures  1B,C). One notable exception is H38, which borders 
an FcγR contact residue and is substituted to Q in all MM sub-
classes. In contrast, across the human IgG subclasses, a number 
of substitutions are present in or adjacent to contact residues 
(Figure 1A), particularly among those at the start of the CH2 
domain near the hinge. Visualization of these sites of human 
subclass variation is consistent with their well-characterized 
differences in FcγR recognition (Figure 1D). In contrast, when 
MM subclasses are compared to each other, there are relatively 
fewer and generally more conservative substitutions at the 
interface (Figures 1E,F). However, several substitutions might 
be expected to impact FcγR recognition. First, MM IgG2 has a 
deletion of P2, proximal to FcγR contact residues. Second, MM 
IgG3 and IgG4 possess an A97G substitution in an FcγR contact 
residue. Interestingly, the A97G substitution is also present in 
human IgG2 and IgG4. Overall, structural assessment of sites 
of variation also suggests that MM subclass activities might 
be expected to vary less considerably than their human IgG 
counterparts.
Biophysical characterization of  
MM igg recognition by human Fcγr
The ability of the high affinity human FcγRI to recognize each 
MM subclass was determined in a multiplex assay that quantified 
IgG bound to FcγR-conjugated fluorescently coded microspheres. 
The high affinity human FcγRI receptor was observed to favor 
MM IgG1 > IgG2 > IgG3 and IgG4 (Figure 2A), in contrast to 
human IgGs, which are favored as IgG1/IgG3 > IgG4 > IgG2 (11, 
39). The interaction between MM IgG and FcγRI was found to be 
highly dependent on IgG glycosylation (Figure  2B). Complete 
removal of N-linked IgG glycans with PNGase F ablated FcγRI 
recognition and glycan restriction with the IgG glycosidase 
EndoS, which leaves a core GlcNac that is variably fucosylated, 
likewise compromised binding.
Significant glycosylation sensitivity was also observed for the 
low affinity FcγRII and FcγRIII receptors using the multiplexing 
assay, where EndoS treatment significantly reduced the binding 
of MM IgG1 to FcγR-conjugated beads (Figure  3A). Glycan 
dependence was probed when IgG multimers were present in 
the antibody preparations to facilitate binding and indicated that 
glycan was necessary for recognition of even multimeric IgG. 
Similar results were observed following treatment with PNGaseF 
and across all MM subclasses and polyclonal serum IgG (data not 
shown). While the glycosylation profiles of CHO-derived MM 
IgG subclasses were relatively uniform and dominated by fuco-
sylated non- and mono-galactosylated (G0F and G1F) species, 
serum-derived MM IgG exhibited a considerably more complex 
glycoprofile including many peaks comprised of sialylated glyco-
forms (Figures 3B,C).
To characterize the affinity of monomeric MM IgG sub-
classes and rhesus serum-derived polyclonal IgG toward human 
FcγRII and FcγRIII receptors, a series of label-free kinetic 
experiments was conducted. Importantly, the use of SPR for 
this purpose offers greater sensitivity in characterizing low 
affinity interactions and enabled evaluation without reliance 
on detection reagents, which have the potential to introduce 
confounding factors. Indeed, the anti-CH1 reagents commonly 
employed to immobilize antibodies reliably maintained asso-
ciation to some but not all MM IgG subclasses, and therefore 
FigUre 1 | sequence and structural differences between human and Macaca mulatta (MM) immunoglobulin g (igg). (a) Sequence alignment of human 
IgG subclasses with the recombinant monoclonal rhesus macaque IgG. CH2 and CH3 domains are denoted in gray, whereas the N-linked glycosylation site and 
known human IgG Fc gamma receptors (FcγR) contact residues (35–38) are annotated in blue. (B) Structural model of human IgG1 CH2 and CH3 domains (ribbon) 
in complex with human FcγRIIIa extracellular domain (space-fill) in which amino acids that differ between rhesus and human IgG1 sequences for each species are 
colored orange (pdb 1T89). H38Q and oligosaccharides at N297 are illustrated in ball and stick. (c–e). A top-down view of the FcγR binding site, in which 
conserved positions are colored blue and variant positions colored orange. Oligosaccharides at N297 are illustrated in ball and stick. (c) Positional variance in the 
FcγR contact interface between human and MM IgG1. (D) Positional variance in the FcγR contact interface among the human IgG subclasses. (e) Positional 
variance in the FcγR contact interface among MM IgG subclasses. (F) Structural model of human IgG1 (ribbon) in complex with human FcγRIIIa (space-fill) in which 
amino acids that differ between MM IgG subclasses are colored orange. H38Q is illustrated in ball and stick.
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antibodies were covalently conjugated directly to SPR chips. 
The mean binding affinities (KD) for MM IgG subclasses 
across human FcγR allotypic variants were determined by 
global fitting of kinetic data using a 1:1 model (Table  2), 
and representative curve fits are shown in Figure  4. FcγRIII 
variants showed a strong preference toward MM IgG1 relative 
to all other subclasses, whereas FcγRII variants exhibited less 
variable affinities across MM subclasses. Notably, a sample of 
purified polyclonal serum IgG exhibited binding affinities with 
good agreement to MM IgG1.
composition and Properties of Polyclonal 
MM serum igg
To further evaluate whether the recombinantly produced MM 
IgGs reflected the behavior of naturally derived plasma IgG 
secreted by B cells, we conducted SPR experiments on a set of puri-
fied polyclonal antibodies from 10 MM (Figure 5B). Consistent 
with the commercially available preparation in Figure  5A, 
natural IgG exhibited an FcγR-binding profile highly consistent 
with MM IgG1, suggesting that MM serum IgG may be predomi-
nantly comprised of IgG1 or allotypic variants of other subclasses 
FigUre 3 | glycosylation state of Macaca mulatta (MM) immunoglobulin g (igg) and glycan requirement for binding to low affinity human Fcγr. (a) 
Recombinant monoclonal rhesus macaque IgG (MM IgG1–4) with minor contamination with dimeric IgG and purified polyclonal rhesus macaque plasma IgG (MM 
pIgG) were either untreated or treated with EndoS (red) leaving a variably fucosylated GlcNac core of the Fc domain glycan. Triplicate measurements at 5 × 10−7 M 
MM IgG1 in one representative multiplex assay are presented. (B,c) IgG glycosylation as determined by glycan HPLC for MM IgG1 (B) and polyclonal IgG derived 
from MM serum (c). Peak identities were determined by exoglycosidase digests and glycan controls.
FigUre 2 | recognition of Macaca mulatta (MM) immunoglobulin g (igg) by human Fcγri. (a) Recombinant monoclonal rhesus macaque IgG (MM 
IgG1–4) with minor contamination with dimeric IgG and purified polyclonal rhesus macaque plasma IgG (MM pIgG) were titrated for binding to the high affinity 
human FcγRI. Triplicates representative of two independent experiments are presented. (B) IgG samples were treated with PNGaseF (blue) or EndoS (red) to remove 
either all or all but the variably fucosylated GlcNac core of the Fc domain glycan. Triplicate dilutions are presented.
TaBle 1 | relative Fc sequence conservation across species.
MM igg1 MM igg2 MM igg3 MM igg4
ch1–hinge–ch2–ch3
Hu IgG1 90.7 88.5 89.2 88.8
Hu IgG2 87.1 88.3 87.7 88.1
Hu IgG3 78.5 76.4 78.2 76.4
Hu IgG4 87.4 87.2 89.2 90.2
MM IgG1 – 89.8 91 89.2
ch2
Hu IgG1 90.0 89.1 90.9 92.7
Hu IgG2 82.7 84.5 88.2 90.0
Hu IgG3 87.3 87.3 89.1 90.9
Hu IgG4 85.5 86.4 91.8 93.6
MM IgG1 – 90.9 92.7 90.9
Matrix presents the percent identity between the entire Fc and within the CH2 domain 
only.
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with IgG1-like FcγR binding. While IgG mixtures with different 
fractionation profiles have been resolved chromatographically 
(6), a general understanding of the subclass composition of MM 
plasma IgG has been lacking.
A limited number of studies report use of subclass-specific 
detection reagents (40). We evaluated a set of α-MM IgG subclass 
detection reagents for their subclass specificity and sensitivity. 
In a multiplex assay, we observed that IgG2 and IgG3 could be 
reliably distinguished from other recombinant subclasses using 
detection reagents raised against their hinges (Figure  6A), but 
that the available α-MM IgG1 detection antibody exhibited some 
cross-reactivity with MM IgG3. No detection reagent for MM 
IgG4 was available. Similar results were observed when these 
subclass detection antibodies were used in an ELISA format to 
detect recombinant CD8α-specific MM IgG bound to plates 
coated with CD8α (Figure 6C).
When these detection reagents were used to characterize the 
subclass composition of plasma IgG across a set of 36 MM serum 
IgG samples in a multiplexed fluorescent microsphere assay, 
only low levels of IgG2 or IgG3 were observed (Figure 6B). To 
understand the sensitivity limits of these reagents, analysis of 
defined mixtures of the recombinant monoclonals indicated that 
IgG2 and IgG3 could be detected even when prevalent at less than 
10% by mass. When these reagents were used in ELISA format to 
detect MM subclasses from recombinant mAbs and polyclonal 
TaBle 2 | affinity of Macaca mulatta (MM) immunoglobulin g (igg) subclasses for low affinity human Fcγr.
Fcγr MM igg1 MM igg2 MM igg3 MM igg4
Experiment 1 FcγRIIa H131 7 ± 1 11 ± 4 27 ± 9 23 ± 5
FcγRIIa R131 9 ± 4 32 ± 7 11 ± 2 11 ± 2
FcγRIIb/c 36 ± 7 90 ± 43a 46 ± 12a 33 ± 3
FcγRIIIa V158 4 ± 2 21 ± 13 84 ± 84a 32 ± 11a
FcγRIIIa F158 4 ± 1 48 ± 51a 78 ± 52a 48 ± 26a
FcγRIIIb NA1 18 ± 7 700 ± 430a 700 ± 430a 500 ± 370a
FcγRIIIb NA2 13 ± 5 400 ± 420a 510 ± 370a 730 ± 380a
FcγRIIIb SH 15 ± 8 530 ± 340a 740 ± 370a 465 ± 400a
Experiment 2 FcγRIIa H131 9 ± 2 11 ± 4 16 ± 4 20 ± 10
FcγRIIa R131 21 ± 9 41 ± 16a 25 ± 20 20 ± 6
FcγRIIb/c 53 ± 14a 125 ± 37a 38 ± 7 32 ± 7a
FcγRIIIa V158 5 ± 2 14 ± 11 27 ± 33 29 ± 17
FcγRIIIa F158 8 ± 2 15 ± 4 33 ± 4a 17 ± 1
FcγRIIIb NA1 14 ± 6 250 ± 320a 210 ± 170a 120 ± 80a
FcγRIIIb NA2 15 ± 3 32 ± 2a 270 ± 420a 270 ± 67a
FcγRIIIb SH 9 ± 4 80 ± 100a 350 ± 860a 340 ± 500a
Binding affinities (KD) of MM IgG subclasses for low affinity human FcγR allotypic variants as determined by surface plasmon resonance. Data are reported as the mean in 
micromolar ± SD across at least three independent measurements.
aValue is outside of the concentration range used and is therefore less reliable.
FigUre 4 | representative surface plasmon resonance (sPr) data and curve fits. Raw SPR signals (black) and kinetic curve fits (red) in a 1:1 model are 
presented for the Macaca mulatta immunoglobulin G (IgG) subclasses and a purified serum IgG sample for FcγRIIa H131 and FcγRIIIb SH allotypes.
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sera adhered to plates, IgG2 and IgG3 could be detected above 
background in the single polyclonal sera sample evaluated in 
this format (Figure  6D). Using absorbance signal to estimate 
concentration, however, indicated that IgG2 and IgG3 are likely 
minor components.
We next sought to assess IgG subclass concentrations in serum 
using semi-quantitative mass spectrometry. Manual inspection 
of the IgG subclass protein sequences suggested that subclass-
unique tryptic peptide sequences could be used to both confirm 
the identity of individual subclasses within mixed samples or 
serum, as well as quantify the relative abundances in these 
samples. To do so, recombinant purified IgG subclasses were 
analyzed as pure samples as well as diluted in known ratios to 
one another to produce mixed IgG samples for development of 
a standard curve. These mixed standards were then separated 
by SDS-PAGE, digested with trypsin, and analyzed by high 
performance mass spectrometry. Unique peptide sequences were 
identified for all subclasses except IgG3; the peptide sequence 
that uniquely identifies this subclass is large and hydrophobic, 
which precluded its routine analysis from these mixtures. For the 
remaining three subclasses, peptide peak area standard curves 
were generated as a fraction of the total IgG analyzed, which 
enabled linear regression-based quantification of IgG subclasses 
1, 2, and 4 from macaque sera (Table 3). Consistent with results 
noted above, IgG1 was the most abundant of the subclasses in 
these samples, followed by IgG2 and IgG4. Although IgG3 was 
unambiguously qualitatively identified in some of these serum 
samples, the poor quantitative performance of its unique peptide 
prohibited accurate estimation of its abundance.
effector Function of MM igg subclasses
To assess the functional impact(s) of observed differences in FcγR 
binding between MM subclasses, we next evaluated the activity 
FigUre 5 | affinity of rhesus immunoglobulin g (igg) for low affinity 
human Fcγr. (a,B) Equilibrium binding affinity (KD in micromolar) of 
recombinant monoclonal rhesus IgG subclasses [Macaca mulatta (MM) 
IgG1–4] as well as a commercially supplied sample of purified polyclonal 
rhesus macaque plasma IgG (MM pIgG) to the low affinity human FcγR. Bars 
denote the mean of two to six replicates, in two separate experiments (upper 
and lower panels) using different preparations of FcγR. (B) Equilibrium 
binding affinity (KD in micromolar) of 10 randomly selected purified rhesus 
macaque plasma IgG samples. Bars and whiskers denote the median and 
interquartile range.
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of each subclass in an assay measuring antibody-driven induction 
of human NK CD107a surface expression via cross-linking of 
FcγRIIIa V158, a surrogate indicator of NK cell cytokine release 
(30), cytotoxicity (29), and ADCC (14, 31, 32). Subclass-switched 
versions of a human mAb were able to induce NK activation 
only in IgG1 and IgG3 forms (Figure 7A). In contrast, all MM 
IgG subclasses were capable of activating the same preparation 
of NK-92 cells (Figure  7B), though one experiment with less 
responsive NK-92 cells more dramatically differentiated among 
MM subclasses. Consistent with biophysical data, this functional 
assessment demonstrated that MM IgG1 and serum-derived MM 
pIgG exhibited the greatest induction of NK cell activity.
To evaluate the effector function of a phagocytic human effec-
tor cell with a more complex FcγR expression profile, we next 
evaluated the activity of each subclass in a commonly utilized 
assay of ADCP, in which monocytic human THP-1 cells are used 
as effectors and their uptake of antibody-opsonized fluorescent 
beads is quantified by flow cytometry (33). Beads were covalently 
conjugated with CD8α, and the phagocytic activity of each MM 
IgG subclass was determined across a titration range (Figure 8A). 
THP-1 cells express a range of FcγRs, including FcγRI, FcγRIIa, 
FcγRIIb, and sometimes FcγRIIIa, but phagocytic activity is most 
tightly linked to FcγRII ligation with some contribution from 
FcγRI (33, 41). In contrast to human IgG subclasses (Figure 8B), 
which exhibit dramatically different phagocytic potencies, MM 
IgGs demonstrated relatively consistent activity when either 
the Fv target antigen CD8α (Figure  8C) or an anti-MM IgG 
polyclonal antibody-based capture (data not shown) was used to 
form immune complexes. This ADCP activity profile observed 
was consistent with affinity for FcγRII by SPR. Differences in 
phagocytic activity among MM subclasses were considerably 
less pronounced than activity differences observed in the NK 
activation assay (Figure 7B) or in phagocytosis activity among 
human IgG subclasses (Figure 8B), which was assessed using an 
anti-human Fab capture bead and myeloma-derived human IgGs 
of approximately 90% purity.
Lastly, each anti-CD8α IgG representing the four rhesus 
subclasses was passively administered to two rhesus macaques 
at 50 mg/kg, and in vivo effector function was assessed by quan-
tifying CD8+ T cells in blood. To avoid cross-blocking by the 
administered anti-CD8α, CD8+ T cells were identified by whole 
blood immunophenotyping as CD3+CD4−. The percent change 
from baseline in the absolute number of targeted cells is shown 
in Figure 9. Anti-CD8α antibodies of the IgG1 and IgG2 subclass 
resulted in prompt loss of the targeted cell subset from blood to 
<20% of baseline. The mean extent and duration of CD8+ T cell 
depletion was greater in animals treated with IgG1 than with IgG2. 
The extent of CD8+ T cell depletion in animals treated with IgG3 
or IgG4 never less than 40% of baseline. Furthermore, the average 
number of CD8+ T cells in animals treated with IgG4 exceeded 
the baseline values after 2 weeks. Despite the similarities in FcγR 
between species, the existence of several MM FcγR allotypic vari-
ants that strongly impact receptor recognition of antibody (42), 
or have been implicated in differential intracellular signaling (43), 
and the limited number of animals in this study precludes rigorous 
differentiation of subclass activity profiles in vivo. However, this 
depletion profile is nonetheless consistent with the biophysical 
and in vitro functional assays, suggesting that MM IgG subclasses 
rank by effector activity as IgG1 > IgG2 > IgG3/4. The striking 
differences in depletion between subclasses appear most consist-
ent with FcγRIII-mediated activity and suggest involvement of 
NK cells.
DiscUssiOn
While the effector function of polyclonal, antigen-specific 
antibodies elicited by candidate vaccines evaluated in NHP has 
often been investigated and tested in vitro using human effector 
cells (2, 5, 13, 15, 18, 44), surprisingly little is known about the 
immunobiology of NHP IgG subclasses and their interaction 
with human FcγRs. As evidence of the significance of Fc domain-
driven effector functions to the in vivo activity of even antibodies 
with highly potent Fv domains continues to accumulate (3, 
45–48), and the relevance that divergent subclass distributions 
in response to vaccination may play in efficacy in humans has 
become more apparent (49–51), an improved understanding 
FigUre 6 | characterization of rhesus immunoglobulin g (igg) subclass composition and detection reagents. (a,B) Multiplex subclassing assays. (a) 
Recombinant monoclonal rhesus macaque IgG [Macaca mulatta (MM) IgG1–4] and pooled purified polyclonal rhesus macaque plasma IgG (MM pIgG) were titrated 
for binding to microspheres conjugated with anti-MM, subclass-specific antibodies (anti-MM IgG1, anti-MM IgG2, anti-MM IgG3), and bound test antibody detected 
by a pan anti-rhesus IgG detection antibody. (B) In a separate experiment, antibody purified from serum samples from 36 naïve MM (black) was likewise evaluated 
to detect the presence of IgG1, IgG2, and IgG3 subclasses. (c,D). ELISA subclassing assays. (c) Sensitivity and specificity of MM subclass detection reagents over 
a titration range when recombinant, CD8α-specific MM IgG subclass antibody test samples were bound to CD8α-conjugated ELISA plates. (D) The composition of 
MM serum IgG in a pooled sample was evaluated via an ELISA in which either non-specifically adhered serum IgG or recombinant MM IgG subclasses as controls 
were detected using a dilution series of the anti-subclass detection reagents.
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of the correspondence of antibody biology between NHP and 
humans is likely to facilitate translational efforts centered on this 
model organism.
Previous studies have indicated that macaque IgG1 induced 
both ADCC and phagocytosis, but that the sole macaque IgG2 
evaluated could not (7, 52–54). In contrast, a recent study of 
cynomolgus IgGs indicated that all subclasses were all able to 
induce lysis of opsonized B cells (11), while a previous study 
evaluating cynomolgus subclasses indicated otherwise (10). One 
confounding factor related to the existing literature regarding 
NHP subclasses is that some cross-species comparisons evaluate 
more identical sequences than within-species comparisons made 
across studies that have apparently utilized different allotypic vari-
ants. These allomorphs could significantly impact study results, 
FigUre 8 | characterization of the phagocytic activity of Macaca mulatta (MM) immunoglobulin g (igg) subclasses and comparison to human igg 
subclasses. (a) Exemplary flow cytometry histograms for a titration of MM IgG1 driving phagocytosis of CD8α-conjugated fluorescent beads. (B) Myeloma-derived 
human IgG1–4 were evaluated in the same assay measuring uptake of fluorescent beads, in this case using beads conjugated with an anti-human Fab reagent. 
Results from one representative experiment with technical replicates are presented. (c) Recombinant monoclonal rhesus macaque IgG (MM IgG1–4) was evaluated 
for its ability to drive phagocytosis of CD8α-conjugated fluorescent beads. Representative results from two of five independent experiments in which duplicate 
titrations were assessed are presented.
FigUre 7 | characterization of natural killer (nK) cell degranulation activity of Macaca mulatta (MM) immunoglobulin g (igg) subclasses and 
comparison to human igg subclasses. (a) Subclass-switched forms of the human VRC01 mAb were evaluated in for ability to drive degranulation of NK-92 cells 
by directly coating a dilution series of IgG onto a 96-well plate. (B) Recombinant rhesus macaque IgG (MM1–4) and polyclonal rhesus macaque plasma IgG (pIgG) 
was likewise evaluated. Results from an assay with less responsive (left, n = 1) or normally responsive NK-92 cells (right, n = 4) are presented.
TaBle 3 | estimates of subclass prevalences in Macaca mulatta serum based on Ms.
animal
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
IgG1 ++++ +++++ ++++ ++++ +++ +++ ++++ +++ +++++ ++++ ++++ ++++ +++++ ++++ ++++ +++ ++++ +++ ++++
IgG2 + ++ + + ++ + + + ++ + ++ ++ ++ ++ ++ ++++ ++ +++ ++
IgG3 nd nd nd nd nd nd * nd * nd nd nd Nd nd * nd * * nd
IgG4 + + + + + + + + + + + + + + + + + + +
Response magnitudes are characterized as follows: nd, not observed; *, not quantified; +, <20%; ++, 20–40%; +++, 40–60%; ++++, 60–80%; +++++, 80–100%.
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and thus, given the limited information regarding the degree of 
allotypic variation among NHP subclasses, caution regarding 
universal application of statements as to subclass activity should 
be maintained. Here, we evaluated a single allotype of each MM 
subclass, from a widely available supply of recombinant protein, 
with a well-documented sequence.
We found that compared to human IgG subclasses, the 
MM subclasses tended to possess a more uniform binding and 
functional profile, with MM IgG1 generally exhibiting the highest 
activity, followed by IgG2, then IgG3/IgG4. Importantly, the bio-
physical and functional characterization here was well-supported 
by sequence and structural homology. Previous sequencing stud-
ies have posited that the MM IgG subclasses resulted from gene 
duplication events subsequent to the evolutionary branchpoint 
from humans based on the observation that MM subclasses are 
more highly related to each other than to their nominal human 
FigUre 9 | In vivo administration of anti-cD8α antibodies representing 
the four rhesus immunoglobulin g subclasses. A single 50 mg/kg dose 
of each antibody was administered IV to two normal rhesus macaques, and 
the change from baseline in absolute number of CD3+CD4− lymphocytes in 
blood was assessed. Each data point represents the average (n = 2) percent 
change from baseline (average of two pretreatment measurements).
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counterparts (7, 9). Sequence conservation among FcγR contact 
residues further supports the observations made here and in 
studies of cynomolgus macaque subclasses that IgG types may 
be rather more uniformly active in NHP than humans (11, 55). 
The biophysical features of IgG subclasses have likely evolved 
differently between species in part due to differences in the selec-
tive pressures individual species are exposed to in their natural 
environments. In particular, differences in immunological strate-
gies addressed at bacteria, parasites, and allergens, against which 
humans often engender IgG2- and/or IgG4-biased responses 
(56–59), and even potential differences in the importance of ame-
lioration of autoimmune or allergic responses, which are often 
associated with subclass switching to IgG4 in humans, between 
species, are suggested by these activity differences.
Notably, a series of studies have evaluated the significance of 
differences in IgG subclass selection on the activity and potential 
mechanistic link to efficacy in human HIV vaccine studies (49–51). 
Because rhesus macaques are the most frequently used preclinical 
model in HIV vaccine evaluation, there has been significant inter-
est in understanding whether differential induction of subclasses 
is also associated with vaccine efficacy in macaques. However, 
together with evaluation of cynomolgus IgG subclasses (11), our 
study finds that the repertoire of antibody FcγR-binding activities 
present in humans is imperfectly matched to those in NHP. The 
more functionally inert human IgG2 and IgG4 subclasses are evi-
dently not well mirrored among NHP subclass variants; and the 
functionally potentiated human IgG3 subclass bears little struc-
tural similarity to any known NHP IgG type. While human IgG1 
and IgG3 demonstrate relatively similar affinities across FcγR, 
human IgG3 has often been observed to demonstrate superior 
activity in cell-based functional assays. These observations may 
be linked to the unique architecture of the human IgG3 hinge, 
which is considerably longer, bears different disulfide bonding 
structure, and is differentially flexible than other subclasses in 
humans. To the extent that these features may be mechanistically 
associated with the observation that IgG3 responses were potenti-
ated among uninfected RV144 vaccine recipients (50), or factor 
into other candidate vaccine responses, they too may be difficult 
to recapitulate in NHP models.
Though the MM IgG subclasses fail to provide exact corre-
spondence to human IgG subtypes, the relatively more uniform 
profile of MM IgGs likely has the advantage of potentially 
reducing sources of variation that could otherwise significantly 
impact antibody activity, the relative composition of plasma, or 
antigen-specific responses. Interestingly, we found in SPR experi-
ments conducted on 10 MM plasma IgG samples that macaque 
serum IgG demonstrated affinity to FcγRs that were generally 
most similar to recombinant MM IgG1. Assuming that glycan 
and allotypic variance play a secondary role to subclass preva-
lence in FcγR-binding, this result implies that serum IgG may be 
predominantly comprised of the IgG1 subclass. Consistent with 
this possibility, but subject to limitations in detection of reagent 
availability and sensitivity, we observed only limited detection of 
IgG2 or IgG3 from two sets of MM serum IgG samples, though it 
is possible that allotypic variance in the IgG hinge region recog-
nized by the anti-subclass detection reagents or other differences 
between naturally derived and recombinant MM IgG may also 
confound the ability to detect MM IgG subclasses. MS-based 
analysis of the subclass composition of serum IgG indicated that 
IgG1 was the predominant species in 18/19 animals, but levels of 
IgG2 estimated from standard curves accounted for an average 
of ~25% of serum immunoglobulin, which, based on results with 
mixtures of defined proportions of recombinant IgG, would have 
been expected to be easily detected with the subclassing reagents. 
Thus, while these data are not completely conclusive regarding 
the subclass composition of rhesus IgG, it is consistent with previ-
ous findings: a prior study found that 13 of 14 mAbs produced 
by rhesus heterohybridomas were consistent with IgG1, while 
only 1/14 was identified as an IgG2 based on restriction digests 
(7). In studies using RT-PCR, relative transcript expression levels 
were observed as follows: IgG1 > IgG2 > IgG3 > IgG4 (9); while 
gel-based quantitation of cDNA amplification of the hinge region 
indicated a relative prevalence of IgG1  >>  IgG3  >  IgG2 (7). 
Indeed, in several earlier studies, transcripts of the IgG4 subclass 
were not observed (7, 60).
While this study does not address potential differences in 
MM IgG activity due to differences in MM FcγR, our charac-
terization of these receptors suggests that they generally exhibit 
similar binding preferences as human FcγR (42). However, some 
allotypic variants bear reduced ability to bind IgG. Additionally, 
some MM FcγR allotypes vary in their intracellular domains, and 
one of these differences was previously associated with more or 
less complete B cell depletion using rituximab (43). Furthermore, 
little is known about MM FcγR expression levels or distribution 
on innate immune cell subsets, which could drive dramatic dif-
ferences in their activity in vivo as compared to human effector 
cell types.
Overall, we find that consistent with inferences from sequence 
and structural models, rhesus macaque IgG subclasses exhibit 
relatively uniform FcγRI and FcγRII binding and phagocytosis 
activity profiles—often in contrast to their nominal human IgG 
counterparts, which exhibit significantly greater structural and 
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functional diversity. MM IgG1 exhibited preferential binding for 
human FcγRIII receptors and accordingly displayed the greatest 
activation of NK cells among the MM subclasses. Consistent with 
biophysical and cell-based assays, and suggestive of the impor-
tance of NK-mediated ADCC, passively administered anti-CD8α 
MM IgG1 supported the most robust depletion of CD8+ T cells 
in vivo, whereas depletion by IgG2 was moderate, and IgG3 and 
IgG4 demonstrated only modest (IgG3) and/or transient (IgG4) 
reduction.
Though previous studies have aimed to characterize the induc-
tion of specific IgG subclasses among vaccinated rhesus macaques 
(61, 62), collectively, the findings in this study suggest that the 
functional differences associated with subclass-switching profiles 
observed in human HIV vaccines cannot be strictly recapitulated 
in NHP vaccine studies. Accordingly, care must be taken not to 
presume the significance of “nominal” correspondence of subclass 
types. Finally, they also indicate that regulation of the posttransla-
tional glycosylation of the Fc domain may play a significant role 
in dictating some MM IgG activities, and that glycoprofiling of 
vaccine-induced antibody responses could be a valuable indicator 
of antibody activities across species. While greater understanding 
of FcγR allotypes and expression patterns represent additional 
critical factors in developing a better understanding of the cor-
respondence of antibody biology between species, identification 
of the similarities and dissimilarities between IgG subclasses is an 
important step to enabling both effective translation of findings in 
NHP studies into the clinic and the investigation of clinical cor-
relates observed in human studies in these key model organisms.
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